Yaozong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yaozong Li has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Amedeo Caflisch
University of Zürich
18 shared publications - Rajiv Kumar Bedi
University of Zürich
13 shared publications Danzhi Huang
Department of Biochemistry, University of Zurich
7 shared publications- Francesco Nai
University of Zürich
5 shared publications František Zálešák
Department of Biochemistry
5 shared publications- Pablo Andrés Vargas-Rosales
Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland
4 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Structure-Based Design of Potent Pan-YTHDF Ligands
The reader proteins YTHDF1-3 recognize m6A-RNA in the cytosol. Here, we present a structure-based medicinal chemistry campaign that culminated in the pan-YTHDF inhibitor 34 (Kd = 0.14 μM for YTHDF2 by calorimetry), which is selective against YTHDC1 and YTHDC2. The high-resolution crystal structures of the complex of YTHDF2 with six members of the series validate the structure-based design. Using the structural information, we designed compound 31 (IC50 = 0.22 μM for YTHDF2) and a negative control, i.e., its methylated analogue 31b. The cellular thermal shift assay provides evidence of YTHDF2 target engagement in cells for inhibitors 34 and 31, while the negative control 31b is inactive. Compounds 34 and 31 inhibit the proliferation of the AML cell lines MOLM-13 and THP-1. The inhibition of the YTHDF readers by 31 increases the level and stability of the transcript of TNFRSF1B. This renders THP-1 cells more sensitive to TNF-α-induced toxicity.
- 3 November 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Open AccessStructure-Based Design of Potent Pan-YTHDF Ligands
The reader proteins YTHDF1-3 recognize m6A-RNA in the cytosol. Here, we present a structure-based medicinal chemistry campaign that culminated in the pan-YTHDF inhibitor 34 (Kd = 0.14 μM for YTHDF2 by calorimetry), which is selective against YTHDC1 and YTHDC2. The high-resolution crystal structures of the complex of YTHDF2 with six members of the series validate the structure-based design. Using the structural information, we designed compound 31 (IC50 = 0.22 μM for YTHDF2) and a negative control, i.e., its methylated analogue 31b. The cellular thermal shift assay provides evidence of YTHDF2 target engagement in cells for inhibitors 34 and 31, while the negative control 31b is inactive. Compounds 34 and 31 inhibit the proliferation of the AML cell lines MOLM-13 and THP-1. The inhibition of the YTHDF readers by 31 increases the level and stability of the transcript of TNFRSF1B. This renders THP-1 cells more sensitive to TNF-α-induced toxicity.
- 14 October 2026
- Published by American Chemical Society (ACS) in Journal of Chemical Theory and Computation
- Vol. 22 (20) , 10988-11003
Recognition Loop Dynamics Differentiates m6A-mRNA Reader Domains of YTHDF Proteins
The three human YTH-domain family proteins (YTHDF1, YTHDF2, and YTHDF3) are highly homologous and recognize the N6-methyladenosine (m6A) modification of mRNA with essentially identical binding modes and affinities. This homogeneity challenges the well-established view that different YTHDF proteins play distinct cellular functions (the specificity view), with an emerging argument that these proteins may instead play redundant roles. To study this apparent discrepancy, we investigated the mechanism of binding of m6A-containing RNA using mutagenesis, X-ray crystallography, isothermal titration calorimetry (ITC), and molecular dynamics simulations. Specifically, we compared different properties of YTHDF proteins, including their binding capacities to m6A-RNA, conformational changes, and homodimerization propensity. Our results show that the YTHDF proteins share an identical binding mode of m6A-RNA, which requires rare protonation of m6A for binding. Additionally, the three proteins share a similar open-closed switch for their recognition loop regulating the m6A binding. On the other hand, ITC data and crystal structures provide consistent evidence that the YTHDF proteins differ significantly in the flexibility of the recognition loop and its conformational preferences. Only YTHDF1 can homodimerize, which prevents binding to m6A-RNA. Furthermore, we integrate the available biophysical and biochemical evidence to define both the shared and distinct features of YTHDF1–3 in m6A-RNA recognition and propose a hybrid model that reconciles the redundancy-specificity debate. Finally, we discuss the limitations of the work and propose experiments for validating the presented model.
- 14 October 2026
- Published by American Chemical Society (ACS) in Journal of Chemical Theory and Computation
- Vol. 22 (20) , 10988-11003
Recognition Loop Dynamics Differentiates m6A-mRNA Reader Domains of YTHDF Proteins
The three human YTH-domain family proteins (YTHDF1, YTHDF2, and YTHDF3) are highly homologous and recognize the N6-methyladenosine (m6A) modification of mRNA with essentially identical binding modes and affinities. This homogeneity challenges the well-established view that different YTHDF proteins play distinct cellular functions (the specificity view), with an emerging argument that these proteins may instead play redundant roles. To study this apparent discrepancy, we investigated the mechanism of binding of m6A-containing RNA using mutagenesis, X-ray crystallography, isothermal titration calorimetry (ITC), and molecular dynamics simulations. Specifically, we compared different properties of YTHDF proteins, including their binding capacities to m6A-RNA, conformational changes, and homodimerization propensity. Our results show that the YTHDF proteins share an identical binding mode of m6A-RNA, which requires rare protonation of m6A for binding. Additionally, the three proteins share a similar open-closed switch for their recognition loop regulating the m6A binding. On the other hand, ITC data and crystal structures provide consistent evidence that the YTHDF proteins differ significantly in the flexibility of the recognition loop and its conformational preferences. Only YTHDF1 can homodimerize, which prevents binding to m6A-RNA. Furthermore, we integrate the available biophysical and biochemical evidence to define both the shared and distinct features of YTHDF1–3 in m6A-RNA recognition and propose a hybrid model that reconciles the redundancy-specificity debate. Finally, we discuss the limitations of the work and propose experiments for validating the presented model.
- Open Access
- 5 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 2159
Molecular basis for the inhibition of de novo DNA methylation by TCL1A
DNA methyltransferases DNMT3A/B mediate de novo DNA methylation, essential for embryonic development and cell fate determination. Dysregulation of DNMT3A/B causes developmental defects and tumorigenesis. TCL1A is critical for embryogenesis but promotes lymphomagenesis when deregulated. Previous studies suggested TCL1A binds DNMT3A/B and inhibits their activity, but the mechanism remained unclear. Here, we report the cryo-EM structure of the DNMT3A-TCL1A complex, which comprises a DNMT3A dimer bound by two TCL1A dimers. TCL1A interacts with the catalytic domain of DNMT3A, overlapping with the DNMT3L-binding site, and induces extended conformational rearrangements. The target recognition domain and catalytic loop shift markedly, reducing DNA accessibility, while the catalytic loop occupies the SAM-binding pocket, thereby blocking methyltransferase activity. Supported by biochemical assays and molecular dynamics simulations, we propose a dynamic inhibition mechanism in which TCL1A exploits DNMT3A conformational plasticity to suppress de novo DNA methylation.
- 5 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 2159
Open AccessMolecular basis for the inhibition of de novo DNA methylation by TCL1A
DNA methyltransferases DNMT3A/B mediate de novo DNA methylation, essential for embryonic development and cell fate determination. Dysregulation of DNMT3A/B causes developmental defects and tumorigenesis. TCL1A is critical for embryogenesis but promotes lymphomagenesis when deregulated. Previous studies suggested TCL1A binds DNMT3A/B and inhibits their activity, but the mechanism remained unclear. Here, we report the cryo-EM structure of the DNMT3A-TCL1A complex, which comprises a DNMT3A dimer bound by two TCL1A dimers. TCL1A interacts with the catalytic domain of DNMT3A, overlapping with the DNMT3L-binding site, and induces extended conformational rearrangements. The target recognition domain and catalytic loop shift markedly, reducing DNA accessibility, while the catalytic loop occupies the SAM-binding pocket, thereby blocking methyltransferase activity. Supported by biochemical assays and molecular dynamics simulations, we propose a dynamic inhibition mechanism in which TCL1A exploits DNMT3A conformational plasticity to suppress de novo DNA methylation.
- Open Access
- 27 June 2025
- Published by American Chemical Society (ACS) in ACS Bio & Med Chem Au
- Vol. 5 (4) , 753-765
Discovery of YTHDF2 Ligands by Fragment-Based Design
N 6-Adenosine methylation is the most abundant modification of mRNA. The three members of the YTH domain family proteins (YTHDF1–3) recognize in the cytoplasm the m6A-RNA modification. We screened a library of about 500,000 fragments (i.e., molecules with 11–20 non-hydrogen atoms) by docking into YTHDF2, which resulted in the identification of six active compounds among 47 tested in vitro (hit rate of 13%). The acquisition of 28 analogues of the docking hits provided an additional set of 10 active compounds (IC50 < 100 μM). Protein crystallography-guided optimization of a ligand-efficient fragment by the synthesis of 32 derivatives culminated in a series of YTHDF2 ligands, which show low-micromolar affinity measured by a fluorescence polarization (FP) assay and a homogeneous time-resolved fluorescence-based (HTRF) assay. The series is characterized by very favorable ligand efficiency (of about 0.3–0.4 kcal/mol per non-hydrogen atom). Compound 23 binds to YTHDF2 according to the FP and HTRF assays with a K d value of 1.3 μM and an IC50 value of 11 μM, respectively, and it is selective against all of the other YTH reader proteins. Several compounds of the series bind to the three YTHDF proteins with similar low-micromolar affinity, while they are less potent for YTHDC1 and YTHDC2. In contrast, compounds 17 and 30 bind also to YTHDC2, with K d of 6.3 and 4.9 μM, respectively. We also disclose six crystal structures of YTHDF2 in the complex with the fragments identified by docking.
- 27 June 2025
- Published by American Chemical Society (ACS) in ACS Bio & Med Chem Au
- Vol. 5 (4) , 753-765
Open AccessDiscovery of YTHDF2 Ligands by Fragment-Based Design
N 6-Adenosine methylation is the most abundant modification of mRNA. The three members of the YTH domain family proteins (YTHDF1–3) recognize in the cytoplasm the m6A-RNA modification. We screened a library of about 500,000 fragments (i.e., molecules with 11–20 non-hydrogen atoms) by docking into YTHDF2, which resulted in the identification of six active compounds among 47 tested in vitro (hit rate of 13%). The acquisition of 28 analogues of the docking hits provided an additional set of 10 active compounds (IC50 < 100 μM). Protein crystallography-guided optimization of a ligand-efficient fragment by the synthesis of 32 derivatives culminated in a series of YTHDF2 ligands, which show low-micromolar affinity measured by a fluorescence polarization (FP) assay and a homogeneous time-resolved fluorescence-based (HTRF) assay. The series is characterized by very favorable ligand efficiency (of about 0.3–0.4 kcal/mol per non-hydrogen atom). Compound 23 binds to YTHDF2 according to the FP and HTRF assays with a K d value of 1.3 μM and an IC50 value of 11 μM, respectively, and it is selective against all of the other YTH reader proteins. Several compounds of the series bind to the three YTHDF proteins with similar low-micromolar affinity, while they are less potent for YTHDC1 and YTHDC2. In contrast, compounds 17 and 30 bind also to YTHDC2, with K d of 6.3 and 4.9 μM, respectively. We also disclose six crystal structures of YTHDF2 in the complex with the fragments identified by docking.
- Open Access
- 19 June 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Discovery of YTHDF2 ligands by fragment-based design
N6-Adenosine methylation is the most abundant modification of mRNA. The three members of the YTH domain family proteins (YTHDF1-3) recognize in the cytoplasm the m6A-RNA modification. We screened a library of about 500,000 fragments (i.e., molecules with 11 to 20 non-hydrogen atoms) by docking into YTHDF2, which resulted in the identification of six active compounds among 47 tested in vitro (hit rate of 13%). The acquisition of 28 analogues of the docking hits provided an additional set of 10 active compounds (IC50 < 100 µM). Protein crystallography-guided optimization of a ligandefficient fragment by the synthesis of 32 derivatives culminated in a series of YTHDF2 ligands which show low-micromolar affinity measured by a fluorescence-polarization (FP) assay and a homogeneous time-resolved fluorescence-based (HTRF) assay. The series is characterized by very favorable ligand efficiency (of about 0.3 – 0.4 kcal/mol per non-hydrogen atom). Compound 23 binds to YTHDF2 according to the FP and HTRF assays with a Kd value of 1.3 µM and IC50 value of 11 µM, respectively, and it is selective against all the other YTH reader proteins. Several compounds of the series bind to the three YTHDF proteins with similar low-micromolar affinity, while they are less potent for YTHDC1 and YTHDC2. In contrast, compounds 17 and 30 bind also to YTHDC2, with Kd of 6.3 µM and 4.9 µM, respectively. We also disclose six crystal structures of YTHDF2 in the complex with the fragments identified by docking.
- 19 June 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDiscovery of YTHDF2 ligands by fragment-based design
N6-Adenosine methylation is the most abundant modification of mRNA. The three members of the YTH domain family proteins (YTHDF1-3) recognize in the cytoplasm the m6A-RNA modification. We screened a library of about 500,000 fragments (i.e., molecules with 11 to 20 non-hydrogen atoms) by docking into YTHDF2, which resulted in the identification of six active compounds among 47 tested in vitro (hit rate of 13%). The acquisition of 28 analogues of the docking hits provided an additional set of 10 active compounds (IC50 < 100 µM). Protein crystallography-guided optimization of a ligandefficient fragment by the synthesis of 32 derivatives culminated in a series of YTHDF2 ligands which show low-micromolar affinity measured by a fluorescence-polarization (FP) assay and a homogeneous time-resolved fluorescence-based (HTRF) assay. The series is characterized by very favorable ligand efficiency (of about 0.3 – 0.4 kcal/mol per non-hydrogen atom). Compound 23 binds to YTHDF2 according to the FP and HTRF assays with a Kd value of 1.3 µM and IC50 value of 11 µM, respectively, and it is selective against all the other YTH reader proteins. Several compounds of the series bind to the three YTHDF proteins with similar low-micromolar affinity, while they are less potent for YTHDC1 and YTHDC2. In contrast, compounds 17 and 30 bind also to YTHDC2, with Kd of 6.3 µM and 4.9 µM, respectively. We also disclose six crystal structures of YTHDF2 in the complex with the fragments identified by docking.
- Open Access
- 24 October 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Structural insights into the inhibition mechanism of fungal GWT1 by manogepix
Glycosylphosphatidylinositol (GPI) acyltransferase is crucial for the synthesis of GPI-anchored proteins. Targeting the fungal glycosylphosphatidylinositol acyltransferase GWT1 by manogepix is a promising antifungal strategy. However, the inhibitory mechanism of manogepix remains unclear. Here, we present cryo-EM structures of yeast GWT1 bound to the substrate (palmitoyl-CoA) and inhibitor (manogepix) at 3.3 Å and 3.5 Å, respectively. GWT1 adopts a unique fold with 13 transmembrane (TM) helixes. The palmitoyl-CoA inserts into the chamber among TM4, 5, 6, 7, and 12. The crucial residues (D145 and K155) located on the loop between TM4 and TM5 potentially bind to the GPI precursor, contributing to substrate recognition and catalysis, respectively. The antifungal drug, manogepix, occupies the hydrophobic cavity of the palmitoyl-CoA binding site, suggesting a competitive inhibitory mechanism. Structural analysis of resistance mutations elucidates the drug specificity and selectivity. These findings pave the way for the development of potent and selective antifungal drugs targeting GWT1.
- 24 October 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Open AccessStructural insights into the inhibition mechanism of fungal GWT1 by manogepix
Glycosylphosphatidylinositol (GPI) acyltransferase is crucial for the synthesis of GPI-anchored proteins. Targeting the fungal glycosylphosphatidylinositol acyltransferase GWT1 by manogepix is a promising antifungal strategy. However, the inhibitory mechanism of manogepix remains unclear. Here, we present cryo-EM structures of yeast GWT1 bound to the substrate (palmitoyl-CoA) and inhibitor (manogepix) at 3.3 Å and 3.5 Å, respectively. GWT1 adopts a unique fold with 13 transmembrane (TM) helixes. The palmitoyl-CoA inserts into the chamber among TM4, 5, 6, 7, and 12. The crucial residues (D145 and K155) located on the loop between TM4 and TM5 potentially bind to the GPI precursor, contributing to substrate recognition and catalysis, respectively. The antifungal drug, manogepix, occupies the hydrophobic cavity of the palmitoyl-CoA binding site, suggesting a competitive inhibitory mechanism. Structural analysis of resistance mutations elucidates the drug specificity and selectivity. These findings pave the way for the development of potent and selective antifungal drugs targeting GWT1.
- Open Access
- 8 August 2024
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 4 (9) , 3466-3474
Structure-Based Design of CBP/EP300 Degraders: When Cooperativity Overcomes Affinity
We present the development of dCE-2, a structurally novel PROTAC targeting the CREB-binding protein (CBP) and E1A-associated protein (EP300)-two homologous multidomain enzymes crucial for enhancer-mediated transcription. The design of dCE-2 was based on the crystal structure of an in-house bromodomain (BRD) inhibitor featuring a 3-methyl-cinnoline acetyl-lysine mimic acetyl-lysine mimic discovered by high-throughput fragment docking. Our study shows that, despite its modest binding affinity to CBP/EP300-BRD, dCE-2's remarkable protein degradation activity stems from its good cooperativity, which we demonstrate by the characterization of its ternary complex formation both in vitro and in cellulo. Molecular dynamics simulations indicate that in aqueous solvents, this active degrader populates both folded and extended conformations, which are likely to promote cell permeability and ternary complex formation, respectively.
- 8 August 2024
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 4 (9) , 3466-3474
Open AccessStructure-Based Design of CBP/EP300 Degraders: When Cooperativity Overcomes Affinity
We present the development of dCE-2, a structurally novel PROTAC targeting the CREB-binding protein (CBP) and E1A-associated protein (EP300)-two homologous multidomain enzymes crucial for enhancer-mediated transcription. The design of dCE-2 was based on the crystal structure of an in-house bromodomain (BRD) inhibitor featuring a 3-methyl-cinnoline acetyl-lysine mimic acetyl-lysine mimic discovered by high-throughput fragment docking. Our study shows that, despite its modest binding affinity to CBP/EP300-BRD, dCE-2's remarkable protein degradation activity stems from its good cooperativity, which we demonstrate by the characterization of its ternary complex formation both in vitro and in cellulo. Molecular dynamics simulations indicate that in aqueous solvents, this active degrader populates both folded and extended conformations, which are likely to promote cell permeability and ternary complex formation, respectively.
- Open Access
- 24 May 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (11) , 9516-9535
Structure-Based Design of a Potent and Selective YTHDC1 Ligand
N6-Adenosine methylation (m6A) is a prevalent post-transcriptional modification of mRNA, with YTHDC1 being the reader protein responsible for recognizing this modification in the cell nucleus. Here, we present a protein structure-based medicinal chemistry campaign that resulted in the YTHDC1 inhibitor 40, which shows an equilibrium dissociation constant (Kd) of 49 nM. The crystal structure of the complex (1.6 Å resolution) validated the design. Compound 40 is selective against the cytoplasmic m6A-RNA readers YTHDF1-3 and YTHDC2 and shows antiproliferative activity against the acute myeloid leukemia (AML) cell lines THP-1, MOLM-13, and NOMO-1. For the series of compounds that culminated into ligand 40, the good correlation between the affinity in the biochemical assay and antiproliferative activity in the THP-1 cell line provides evidence of YTHDC1 target engagement in the cell. The binding to YTHDC1 in the cell is further supported by the cellular thermal shift assay. Thus, ligand 40 is a tool compound for studying the role of YTHDC1 in AML.
- 24 May 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (11) , 9516-9535
Open AccessStructure-Based Design of a Potent and Selective YTHDC1 Ligand
N6-Adenosine methylation (m6A) is a prevalent post-transcriptional modification of mRNA, with YTHDC1 being the reader protein responsible for recognizing this modification in the cell nucleus. Here, we present a protein structure-based medicinal chemistry campaign that resulted in the YTHDC1 inhibitor 40, which shows an equilibrium dissociation constant (Kd) of 49 nM. The crystal structure of the complex (1.6 Å resolution) validated the design. Compound 40 is selective against the cytoplasmic m6A-RNA readers YTHDF1-3 and YTHDC2 and shows antiproliferative activity against the acute myeloid leukemia (AML) cell lines THP-1, MOLM-13, and NOMO-1. For the series of compounds that culminated into ligand 40, the good correlation between the affinity in the biochemical assay and antiproliferative activity in the THP-1 cell line provides evidence of YTHDC1 target engagement in the cell. The binding to YTHDC1 in the cell is further supported by the cellular thermal shift assay. Thus, ligand 40 is a tool compound for studying the role of YTHDC1 in AML.
- Open Access
- 12 March 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
The catalytic mechanism of the RNA methyltransferase METTL3
The complex of methyltransferase-like proteins 3 and 14 (METTL3-14) is the major enzyme that deposits N6-methyladenosine (m6A) modifications on messenger RNA (mRNA) in humans. METTL3-14 plays key roles in various biological processes through its methyltransferase (MTase) activity. However, little is known about its substrate recognition and methyl transfer mechanism from its cofactor and methyl donor S-adenosylmethionine (SAM). Here, we study the MTase mechanism of METTL3-14 by a combined experimental and multiscale simulation approach using bisubstrate analogues (BAs), conjugates of a SAM-like moiety connected to the N6-atom of adenosine. Molecular dynamics simulations based on crystal structures of METTL3-14 with BAs suggest that the Y406 side chain of METTL3 is involved in the recruitment of adenosine and release of m6A. A crystal structure with a BA representing the transition state of methyl transfer shows a direct involvement of the METTL3 side chains E481 and K513 in adenosine binding which is supported by mutational analysis. Quantum mechanics/molecular mechanics (QM/MM) free energy calculations indicate that methyl transfer occurs without prior deprotonation of adenosine-N6. Furthermore, the QM/MM calculations provide further support for the role of electrostatic contributions of E481 and K513 to catalysis. The multidisciplinary approach used here sheds light on the (co)substrate binding mechanism, catalytic step, and (co)product release, and suggests that the latter step is rate-limiting for METTL3. The atomistic information on the substrate binding and methyl transfer reaction of METTL3 can be useful for understanding the mechanisms of other RNA MTases and for the design of transition state analogues as their inhibitors.
- 12 March 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Open AccessThe catalytic mechanism of the RNA methyltransferase METTL3
The complex of methyltransferase-like proteins 3 and 14 (METTL3-14) is the major enzyme that deposits N6-methyladenosine (m6A) modifications on messenger RNA (mRNA) in humans. METTL3-14 plays key roles in various biological processes through its methyltransferase (MTase) activity. However, little is known about its substrate recognition and methyl transfer mechanism from its cofactor and methyl donor S-adenosylmethionine (SAM). Here, we study the MTase mechanism of METTL3-14 by a combined experimental and multiscale simulation approach using bisubstrate analogues (BAs), conjugates of a SAM-like moiety connected to the N6-atom of adenosine. Molecular dynamics simulations based on crystal structures of METTL3-14 with BAs suggest that the Y406 side chain of METTL3 is involved in the recruitment of adenosine and release of m6A. A crystal structure with a BA representing the transition state of methyl transfer shows a direct involvement of the METTL3 side chains E481 and K513 in adenosine binding which is supported by mutational analysis. Quantum mechanics/molecular mechanics (QM/MM) free energy calculations indicate that methyl transfer occurs without prior deprotonation of adenosine-N6. Furthermore, the QM/MM calculations provide further support for the role of electrostatic contributions of E481 and K513 to catalysis. The multidisciplinary approach used here sheds light on the (co)substrate binding mechanism, catalytic step, and (co)product release, and suggests that the latter step is rate-limiting for METTL3. The atomistic information on the substrate binding and methyl transfer reaction of METTL3 can be useful for understanding the mechanisms of other RNA MTases and for the design of transition state analogues as their inhibitors.
- Open Access
- 22 February 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 12
The catalytic mechanism of the RNA methyltransferase METTL3
The complex of methyltransferase-like proteins 3 and 14 (METTL3-14) is the major enzyme that deposits N6-methyladenosine (m6A) modifications on mRNA in humans. METTL3-14 plays key roles in various biological processes through its methyltransferase (MTase) activity. However, little is known about its substrate recognition and methyl transfer mechanism from its cofactor and methyl donor S-adenosylmethionine (SAM). Here, we study the MTase mechanism of METTL3-14 by a combined experimental and multiscale simulation approach using bisubstrate analogues (BAs), conjugates of a SAM-like moiety connected to the N6-atom of adenosine. Molecular dynamics simulations based on crystal structures of METTL3-14 with BAs suggest that the Y406 side chain of METTL3 is involved in the recruitment of adenosine and release of m6A. A crystal structure with a bisubstrate analogue representing the transition state of methyl transfer shows a direct involvement of the METTL3 side chains E481 and K513 in adenosine binding which is supported by mutational analysis. Quantum mechanics/molecular mechanics (QM/MM) free energy calculations indicate that methyl transfer occurs without prior deprotonation of adenosine-N6. Furthermore, the QM/MM calculations provide further support for the role of electrostatic contributions of E481 and K513 to catalysis. The multidisciplinary approach used here sheds light on the (co)substrate binding mechanism, catalytic step, and (co)product release catalysed by METTL3, and suggests that the latter step is rate-limiting. The atomistic information on the substrate binding and methyl transfer reaction of METTL3 can be useful for understanding the mechanisms of other RNA MTases and for the design of transition state analogues as their inhibitors.
- 22 February 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 12
Open AccessThe catalytic mechanism of the RNA methyltransferase METTL3
The complex of methyltransferase-like proteins 3 and 14 (METTL3-14) is the major enzyme that deposits N6-methyladenosine (m6A) modifications on mRNA in humans. METTL3-14 plays key roles in various biological processes through its methyltransferase (MTase) activity. However, little is known about its substrate recognition and methyl transfer mechanism from its cofactor and methyl donor S-adenosylmethionine (SAM). Here, we study the MTase mechanism of METTL3-14 by a combined experimental and multiscale simulation approach using bisubstrate analogues (BAs), conjugates of a SAM-like moiety connected to the N6-atom of adenosine. Molecular dynamics simulations based on crystal structures of METTL3-14 with BAs suggest that the Y406 side chain of METTL3 is involved in the recruitment of adenosine and release of m6A. A crystal structure with a bisubstrate analogue representing the transition state of methyl transfer shows a direct involvement of the METTL3 side chains E481 and K513 in adenosine binding which is supported by mutational analysis. Quantum mechanics/molecular mechanics (QM/MM) free energy calculations indicate that methyl transfer occurs without prior deprotonation of adenosine-N6. Furthermore, the QM/MM calculations provide further support for the role of electrostatic contributions of E481 and K513 to catalysis. The multidisciplinary approach used here sheds light on the (co)substrate binding mechanism, catalytic step, and (co)product release catalysed by METTL3, and suggests that the latter step is rate-limiting. The atomistic information on the substrate binding and methyl transfer reaction of METTL3 can be useful for understanding the mechanisms of other RNA MTases and for the design of transition state analogues as their inhibitors.